Excited to announce our license of Gusacitinib to @sanofi for upwards of €545M in upfront and milestones in addition to royalties in the low to mid-teen based on future sales.
"Only 2% of [public] companies [over the last century] were responsible for more than 90% of the aggregate net wealth creation." Long term public market investing = venture capital investing, whether you like it or not! HT @mjmauboussin